Fig. 7

Efficacy, adverse events, and survival outcome of bispecific antibody treatment and ICI combination therapies in patients with Malignant pleural mesothelioma, sarcoma, and LAG-3-positive cancer. A histogram of antitumor activity (a), a forest plot of survival outcomes (b) and incidence of grade ≥ 3 TRAEs, including major adverse effects components (c) of ICIs combination therapies in patients with malignant pleural mesothelioma. A histogram of antitumor activity (d), a forest plot of survival outcomes (e) and common all-grade TRAEs components, including incidence of grade ≥ 3 TRAEs (f) of ICIs combination therapies in patients with sarcoma. A histogram of antitumor activity (g) and common TRAEs components, including incidence of grade ≥ 3 TRAEs (h) of BSABs in patients with LAG-3-positive cancer. MGD013, Tebotelimab; Marg, Margetuximab (anti-HER2); BC, breast cancer; NSCLC, non-small cell lung cancer; aHCC, advanced hepatocellular carcinoma; GC, gastric carcinoma; CRC, colorectal cancer. The ORR, defined as a sum of CR and PR. A bar with a value of 0 means not mentioned in the article